Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avigen licenses North American rights to neuroactive drug
Avigen will pay an upfront $3 million to SDI, as well as payments based on successful clinical and regulatory product development milestones, assumption of certain liabilities and royalty
Avigen will pay an upfront $3 million to SDI, as well as payments based on successful clinical and regulatory product development milestones, assumption of certain liabilities and royalty
The results, which were reported by the scientists in Nature Neuroscience, suggest that restoring fatty-acid levels in the brain may be a promising way to treat obesity. The
The boards of directors of both companies have unanimously approved the revised Johnson & Johnson offer and the Guidant board of directors will recommend that its shareholders vote
The form of the deal includes a combination of $13.25 million cash, as well as debt assumption, minority ownership in the business going forward and deferred sale proceeds.
The investigational new drug (IND) application for PRX302 was filed in December 2005. PRX302 is the first of a novel class of targeted prodrugs based on the company’s
The presence of the fragment, called p95HER-2, in breast cancer tissue correlates closely with lymph node metastasis and earlier recurrence of the disease, suggesting that p95HER-2 is a
More than a third of individuals in the populations studied carry one copy of the at-risk variant and are at an approximately 45% increased risk of the disease
Under the terms of the agreement, BioFocus will expand its SilenceSelect si-RNA-based gene collection with an additional gene set, develop a dedicated cellular assay in the field of
Genelabs is currently working with the FDA in designing an additional trial for the drug in its indication for treating the signs and symptoms of lupus, although the
Pennsaid is currently approved for sale in Canada and several European countries. The phase III trial, named Study 112, was designed with the advice and recommendations provided by